Global Injectable Drug Delivery 麻豆原创 Research Report 2024

Publication ID:

PB502248662

Publication Date:

March 4, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Injectable drug delivery is defined as introduction of a drug or drugs in the patient by using a delivery device. Injectables allow the transport of drugs formulated in liquid form, directly in the body. Even though, they may be designed to transport the drug to specific part of the body.
The global Injectable Drug Delivery market was valued at US$ 421.2 million in 2023 and is anticipated to reach US$ 675.5 million by 2030, witnessing a CAGR of 6.5% during the forecast period 2024-2030.
North America is expected to dominate the market in 2018, Asia is expected to grow at the highest CAGR during the forecast period. This growth in this market is attributed to rising incidence of chronic diseases and growing aging population. In addition, high penetration of self-injection technologies in Asian countries such as China, Japan, and India adds to the demand for injectable devices.
This report aims to provide a comprehensive presentation of the global market for Injectable Drug Delivery, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Injectable Drug Delivery.
Report Scope
The Injectable Drug Delivery market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Injectable Drug Delivery market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Injectable Drug Delivery companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Baxter
Becton, Dickinson
Gerresheimer
Pfizer
Schott
ELI Lilly
Novartis
Terumo
Teva Pharmaceutical
Segment by Type
Skin Injection
Circulatory/Musculoskeletal Injection
Organs Injection
Central Nervous System Injection
Segment by Application
Hospitals & Clinics
麻豆原创 Care Settings
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Injectable Drug Delivery companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Injectable Drug Delivery 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Skin Injection
1.2.3 Circulatory/Musculoskeletal Injection
1.2.4 Organs Injection
1.2.5 Central Nervous System Injection
1.3 麻豆原创 by Application
1.3.1 Global Injectable Drug Delivery 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals & Clinics
1.3.3 麻豆原创 Care Settings
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Injectable Drug Delivery 麻豆原创 Perspective (2019-2030)
2.2 Injectable Drug Delivery Growth Trends by Region
2.2.1 Global Injectable Drug Delivery 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Injectable Drug Delivery Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Injectable Drug Delivery Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Injectable Drug Delivery 麻豆原创 Dynamics
2.3.1 Injectable Drug Delivery Industry Trends
2.3.2 Injectable Drug Delivery 麻豆原创 Drivers
2.3.3 Injectable Drug Delivery 麻豆原创 Challenges
2.3.4 Injectable Drug Delivery 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Injectable Drug Delivery Players by Revenue
3.1.1 Global Top Injectable Drug Delivery Players by Revenue (2019-2024)
3.1.2 Global Injectable Drug Delivery Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Injectable Drug Delivery 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Injectable Drug Delivery Revenue
3.4 Global Injectable Drug Delivery 麻豆原创 Concentration Ratio
3.4.1 Global Injectable Drug Delivery 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Injectable Drug Delivery Revenue in 2023
3.5 Injectable Drug Delivery Key Players Head office and Area Served
3.6 Key Players Injectable Drug Delivery Product Solution and Service
3.7 Date of Enter into Injectable Drug Delivery 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Injectable Drug Delivery Breakdown Data by Type
4.1 Global Injectable Drug Delivery Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Injectable Drug Delivery Forecasted 麻豆原创 Size by Type (2025-2030)
5 Injectable Drug Delivery Breakdown Data by Application
5.1 Global Injectable Drug Delivery Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Injectable Drug Delivery Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Injectable Drug Delivery 麻豆原创 Size (2019-2030)
6.2 North America Injectable Drug Delivery 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Injectable Drug Delivery 麻豆原创 Size by Country (2019-2024)
6.4 North America Injectable Drug Delivery 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Injectable Drug Delivery 麻豆原创 Size (2019-2030)
7.2 Europe Injectable Drug Delivery 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Injectable Drug Delivery 麻豆原创 Size by Country (2019-2024)
7.4 Europe Injectable Drug Delivery 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Injectable Drug Delivery 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Injectable Drug Delivery 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Injectable Drug Delivery 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Injectable Drug Delivery 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Injectable Drug Delivery 麻豆原创 Size (2019-2030)
9.2 Latin America Injectable Drug Delivery 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Injectable Drug Delivery 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Injectable Drug Delivery 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Injectable Drug Delivery 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Injectable Drug Delivery 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Injectable Drug Delivery 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Injectable Drug Delivery 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Baxter
11.1.1 Baxter Company Detail
11.1.2 Baxter Business Overview
11.1.3 Baxter Injectable Drug Delivery Introduction
11.1.4 Baxter Revenue in Injectable Drug Delivery Business (2019-2024)
11.1.5 Baxter Recent Development
11.2 Becton, Dickinson
11.2.1 Becton, Dickinson Company Detail
11.2.2 Becton, Dickinson Business Overview
11.2.3 Becton, Dickinson Injectable Drug Delivery Introduction
11.2.4 Becton, Dickinson Revenue in Injectable Drug Delivery Business (2019-2024)
11.2.5 Becton, Dickinson Recent Development
11.3 Gerresheimer
11.3.1 Gerresheimer Company Detail
11.3.2 Gerresheimer Business Overview
11.3.3 Gerresheimer Injectable Drug Delivery Introduction
11.3.4 Gerresheimer Revenue in Injectable Drug Delivery Business (2019-2024)
11.3.5 Gerresheimer Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Injectable Drug Delivery Introduction
11.4.4 Pfizer Revenue in Injectable Drug Delivery Business (2019-2024)
11.4.5 Pfizer Recent Development
11.5 Schott
11.5.1 Schott Company Detail
11.5.2 Schott Business Overview
11.5.3 Schott Injectable Drug Delivery Introduction
11.5.4 Schott Revenue in Injectable Drug Delivery Business (2019-2024)
11.5.5 Schott Recent Development
11.6 ELI Lilly
11.6.1 ELI Lilly Company Detail
11.6.2 ELI Lilly Business Overview
11.6.3 ELI Lilly Injectable Drug Delivery Introduction
11.6.4 ELI Lilly Revenue in Injectable Drug Delivery Business (2019-2024)
11.6.5 ELI Lilly Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis Injectable Drug Delivery Introduction
11.7.4 Novartis Revenue in Injectable Drug Delivery Business (2019-2024)
11.7.5 Novartis Recent Development
11.8 Terumo
11.8.1 Terumo Company Detail
11.8.2 Terumo Business Overview
11.8.3 Terumo Injectable Drug Delivery Introduction
11.8.4 Terumo Revenue in Injectable Drug Delivery Business (2019-2024)
11.8.5 Terumo Recent Development
11.9 Teva Pharmaceutical
11.9.1 Teva Pharmaceutical Company Detail
11.9.2 Teva Pharmaceutical Business Overview
11.9.3 Teva Pharmaceutical Injectable Drug Delivery Introduction
11.9.4 Teva Pharmaceutical Revenue in Injectable Drug Delivery Business (2019-2024)
11.9.5 Teva Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Baxter
Becton, Dickinson
Gerresheimer
Pfizer
Schott
ELI Lilly
Novartis
Terumo
Teva Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.